2024 Updates on Management of DLBCL

Louisville Hematology Highlights

J. Leonard

Why Are Our Hematopoietic Stem Cells in the Bone Marrow?

Louisville Hematology Highlights

R. Gale

ASH 2024 Insights: POLARIX 5yr Update - Pola-R-CHP vs. R-CHOP in 1L …

2024 ASH Annual Meeting Insights Hub

G. Salles

ASCO® 2024 Summary: "Lymphoma Highlights"

2024 ASCO® Annual Meeting Insights Hub

B. D. Cheson

ASH 2025 Review: Updates in Frontline & R/R DLBCL

University of Colorado Division of Hematology

M. Kamdar

ASH 2024 Review: Key Updates in Non-Hodgkin Lymphoma

Cleveland Clinic Taussig Cancer Institute

P. Caimi

Treating Patients With DLBCL Who Are Not Eligible for CAR-T Therapy

Remy Dulery

Sequencing Cellular Therapy and Bispecific Antibodies in DLBCL

Megan Melody

ASH 2024 Insights: Outcomes With Bispecific Antibodies Post-CAR T-Ce…

2024 ASH Annual Meeting Insights Hub

M. Melody

Updates on Approved CAR-Ts for Lymphomas

Moffitt Cancer Center

J. Chavez

Tafasitamab + Lenalidomide in R/R DLBCL: Updated Results From the L-…

David Bond

ASH 2024 Insights: Timing of CAR-T Failure as a Predictor of Outcome…

2024 ASH Annual Meeting Insights Hub

E. Shumilov

Lymphoma Hot Topics in 2024: Focus on DLBCL and cHL

Yale Cancer Center

T. Sethi

Managing R/R LBCL Patients Treated With Pola-R-CHP in 1L and Are CAR…

University of Colorado Cancer Center

M. Kamdar

Sequencing of Bispecifics With Other Therapies in DLBCL

UChicago Medicine

E. Budde

ASH 2024 Insights: Odronextamab in R/R DLBCL Post-CAR T-Cell Progres…

2024 ASH Annual Meeting Insights Hub

M. Matasar

The Relapsed and Refractory MM Patient: When Immune Approaches Are I…

Joseph Mikhael

Tafasitamab + Lenalidomide vs. CIT for Transplant-Ineligible R/R DLB…

Patrizia Mondello

Tandem 2025 Insights: Real-World Evidence Study Assessing Efficacy a…

Insights from 2025 Tandem Annual Meeting

G. Shouse

R/R DLBCL: Are Bispecific Antibodies Superior to CAR-T?

Moffitt Cancer Center

J. Chavez